- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00840320
Repeat Dose Safety Study for Compound to Treat Anemia
21. juni 2017 oppdatert av: GlaxoSmithKline
A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeat Oral Doses of 1278863A in Healthy Subjects
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound 1278863A in healthy subjects.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Compound 1278863A is a novel small molecule agent, which stimulates erythropoiesis through inhibition of hypoxia-inducible factor (HIF)-prolyl hydroxylases (EGLNs).
This compound is being developed for the treatment of anemia.
Compound 111427 was the first administration of compound 1278863A to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses up to 300 mg in healthy adult subjects.
This study, PHI112842, will be the first administration of compound 1278863A to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of repeat oral doses up to 300 mg for 14 days in healthy adult subjects.
At least 6 subjects will complete each cohort.
Multiple blood samples for pharmacokinetic analyses will be obtained post-dose in each cohort.
Safety will be assessed by measurement of vital signs, cardiac monitoring, collection of adverse event assessments and laboratory safety tests.
Blood samples will be collected for pharmacodynamic analyses.
Studietype
Intervensjonell
Registrering (Faktiske)
24
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- GSK Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 55 år (Voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- Male or female between 18 and 55 years of age, inclusive.
- A female subject must be of non-childbearing potential.
- Male subjects must agree to use one of the acceptable contraception methods listed in the protocol
- Body weight greater than or equal to 50 kg and BMI within the range 19 - 31 kg/m2 (inclusive).
- Capable of giving written informed consent
- QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
Exclusion Criteria:
- The subject has a positive pre-study drug screen.
A hemoglobin value at screening is:
- Male subjects or post-menopausal females: > 15.5 g/dL
- Female subjects: > 14.5 g/dL
The values of hematological parameters at screening are:
MCV: outside the reference range and clinically significant deemed by the investigator and GSK Medical Monitor
The values of the following tests at screening are:
- TIBC: outside the reference range
- Serum iron: outside the reference range
- Serum ferritin: outside the reference range
- A value at screening is greater than the upper limit of reference range for the following clinical laboratory parameters: AST, ALT, direct bilirubin.
- Clinically significant abnormal CPK determined by the investigator and GSK Medical Monitor.
- Calculated creatinine clearance: < 60mL/min
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- A positive test for HIV antibody.
- History of drug abuse or dependence within 6 months of the study.
- History of regular alcohol consumption within 6 months of the study
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study drug
- History of sensitivity to any of the study drugs, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- History of sensitivity to heparin or heparin-induced thrombocytopenia. (if the clinical research unit uses heparin to maintain intravenous cannula patency)
- Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or hepatic function that could interfere with the absorption, metabolism, and/or excretion of the study drugs.
- History of peptic ulcer disease.
- History of malignancy tumor. Non-melanoma skin cancer that has been definitely removed is allowed.
- Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
- Lactating females.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the protocol.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice, exotic citrus fruits, grapefruit hybrids or fruit juices of the prohibited fruits from 7 days prior to the first dose of study medication
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Subject is mentally or legally incapacitated.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: 1
Repeat doses of active at escalating doses
|
15mg, 25mg, 50mg, 150mg
|
Placebo komparator: 2
Repeat doses of placebo
|
matchende placebo
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
adverse events reporting
Tidsramme: throughout study
|
throughout study
|
Safety Labs (hematology)
Tidsramme: Screening, Days -1, 1-3, 5, 7, 9, 11, 14-18, 21, 25, 28
|
Screening, Days -1, 1-3, 5, 7, 9, 11, 14-18, 21, 25, 28
|
vital signs (blood pressure and heart rate)
Tidsramme: Days 1-15, 28
|
Days 1-15, 28
|
12-lead ECG
Tidsramme: Screening, Days 1-2, 4, 6, 8, 10, 12, 14, 28
|
Screening, Days 1-2, 4, 6, 8, 10, 12, 14, 28
|
dual-lead cardiac monitoring (telemetry monitoring)
Tidsramme: Days -1 to 3, 14
|
Days -1 to 3, 14
|
clinical monitoring/observation
Tidsramme: throughout
|
throughout
|
Safety Labs (Chemistry)
Tidsramme: Screening, Days -1, 1-3, 7, 10, 14-15, 17, 21, 28
|
Screening, Days -1, 1-3, 7, 10, 14-15, 17, 21, 28
|
Safety Labs (Urinalysis)
Tidsramme: Screening, Days -1, 1-3, 7, 10, 14-15, 17, 21, 28
|
Screening, Days -1, 1-3, 7, 10, 14-15, 17, 21, 28
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
AUC(0-∞) on Day 1, AUC(0-τ), Cmax, tmax and t1/2, on Days 1 and 14
Tidsramme: Days 1-2, 4, 6, 8, 10, 12, 14-18
|
Days 1-2, 4, 6, 8, 10, 12, 14-18
|
Trough plasma concentrations at the end of the dosing interval
Tidsramme: Days 2, 4, 6, 8, 10 and 12
|
Days 2, 4, 6, 8, 10 and 12
|
Hemoglobin actual values, rate of rise, maximum change from baseline, and rate of decline following stopping of dosing
Tidsramme: Days 1, 7, 14, 21, 28
|
Days 1, 7, 14, 21, 28
|
Fetal hemoglobin actual values, change from baseline, and percent of total hemoglobin
Tidsramme: Days 1, 7, 14, 21, 28
|
Days 1, 7, 14, 21, 28
|
Actual values and change from baseline in erythropoietin
Tidsramme: Days 1-4, 7, 14-15, 18, 21
|
Days 1-4, 7, 14-15, 18, 21
|
Actual values and change from baseline in absolute VEGF
Tidsramme: Days 1-2, 14-15, 18, 21
|
Days 1-2, 14-15, 18, 21
|
Actual values and change from baseline in hepcidin
Tidsramme: Days 1-2, 7, 14-15, 18, 21
|
Days 1-2, 7, 14-15, 18, 21
|
Actual values and change from baseline in total iron binding capacity (TIBC)
Tidsramme: Screening, Days 1, 7, 14, 18, 21
|
Screening, Days 1, 7, 14, 18, 21
|
Actual values and change from baseline in transferring saturation (%)
Tidsramme: Days 1, 7, 14, 18, 21
|
Days 1, 7, 14, 18, 21
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
13. mars 2009
Primær fullføring (Faktiske)
2. september 2009
Studiet fullført (Faktiske)
2. september 2009
Datoer for studieregistrering
Først innsendt
9. februar 2009
Først innsendt som oppfylte QC-kriteriene
9. februar 2009
Først lagt ut (Anslag)
10. februar 2009
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
22. juni 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
21. juni 2017
Sist bekreftet
1. juni 2017
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 112842
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nyresykdom
-
Medical University of ViennaFullførtSekundær hyperparathyroidisme | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | NyreerstatningØsterrike
Kliniske studier på Placebo
-
SamA Pharmaceutical Co., LtdUkjentAkutt bronkitt | Akutt øvre luftveisinfeksjonKorea, Republikken
-
National Institute on Drug Abuse (NIDA)FullførtCannabisbrukForente stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyFullførtMannlige personer med type II diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedFullførtFarmakokinetikk | SikkerhetsproblemerStorbritannia
-
Texas A&M UniversityNutraboltFullførtGlucose and Insulin Response
-
Longeveron Inc.AvsluttetHypoplastisk venstre hjertesyndromForente stater
-
Regado Biosciences, Inc.FullførtFrivillig friskForente stater
-
ItalfarmacoFullførtBecker muskeldystrofiNederland, Italia
-
West Penn Allegheny Health SystemFullførtAstma | Allergisk rhinittForente stater